Roche stakes $2bn on UCB Alzheimer’s disease treatment
30-07-2020
Amgen and Roche target Samsung’s Bioepis in patent suit
01-05-2019
AIPPI 2018: Eli Lilly talks IPRs and biosimilar litigation
26-09-2018
Testing / Shutterstock.com
A Roche subsidiary will be unable to block Amgen from producing the cancer drug Mvasi (bevacizumab), the Court of Appeals for the Federal Circuit has ruled.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Roche, Amgen, drugs, cancer, biotech, Court of Appeals for the Federal Circuit
